Carpenter Kenneth M, McDowell David, Brooks Daniel J, Cheng Wendy Y, Levin Frances R
Division on Substance Abuse, New York State Psychiatric Institute, New York, USA.
Am J Addict. 2009 Jan-Feb;18(1):53-64. doi: 10.1080/10550490802408936.
The present study investigated the efficacy of nefazodone and bupropion-sustained release for treating cannabis dependence. A double-blind, placebo-controlled, piggy back design was employed to assess if nefazodone and bupropion-sustained release increased the probability of abstinence from cannabis and reduced the severity of cannabis dependence and cannabis withdrawal symptoms during a 13-week outpatient treatment program. One-hundred and six participants (Mean = 32 years; females n = 25) were randomized to one of three medication conditions (nefazodone, bupropion-sustained release, or placebo) and participated in a weekly, individually based coping skills therapy program. Results indicated an increased probability of achieving abstinence over the course of treatment and a decrease in the severity of cannabis dependence and the withdrawal symptom of irritability. There were no significant effects demonstrated for nefazodone and bupropion-sustained release on cannabis use or cannabis withdrawal symptoms. The results indicate nefazodone and bupropion-sustained release may have limited efficacy in treating cannabis dependence.
本研究调查了奈法唑酮和安非他酮缓释剂治疗大麻依赖的疗效。采用双盲、安慰剂对照、附加设计，以评估在为期13周的门诊治疗项目中，奈法唑酮和安非他酮缓释剂是否能提高戒除大麻的可能性，并减轻大麻依赖的严重程度和大麻戒断症状。106名参与者（平均年龄 = 32岁；女性n = 25）被随机分配到三种药物治疗组之一（奈法唑酮、安非他酮缓释剂或安慰剂），并参加每周一次的、基于个体的应对技能治疗项目。结果表明，在治疗过程中实现戒除的可能性增加，大麻依赖的严重程度以及易怒的戒断症状有所减轻。奈法唑酮和安非他酮缓释剂对大麻使用或大麻戒断症状没有显著影响。结果表明，奈法唑酮和安非他酮缓释剂在治疗大麻依赖方面可能疗效有限。
